Chemomab Therapeutics Ltd. American Depositary Share (CMMB) is a publicly traded Healthcare sector company. As of May 21, 2026, CMMB trades at $1.70 with a market cap of $11.66M and a P/E ratio of 13.47. CMMB moved +5.81% today. Year to date, CMMB is -11.23%; over the trailing twelve months it is -70.14%. Its 52-week range spans $1.35 to $9.84. Analyst consensus is buy with an average price target of $15.00. Rallies surfaces CMMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Three EASL Studies Show Nebokitug Lowers Fibrosis Scores and IBD Markers: Chemomab presented three EASL 2026 studies showing nebokitug achieved dose-dependent reductions in key fibrosis markers and CCL24-mediated gene expression signatures in PSC patients. Proteomic analyses using an AI model identified composite improvements in ELF score, FibroScan stiffness and PRO-C3, while inflammatory and tissue-remodeling proteins linked to IBD were significantly modulated in 62% of PSC patients with ulcerative colitis or Crohn’s disease.
| Metric | Value |
|---|---|
| Price | $1.70 |
| Market Cap | $11.66M |
| P/E Ratio | 13.47 |
| EPS | $0.12 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.84 |
| 52-Week Low | $1.35 |
| Volume | 655 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-27.65M |
| Gross Margin | 0.00% |
2 analysts cover CMMB: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.00.